DPK guidance withdrawn
This article was originally published in The Tan Sheet
Executive SummaryFDA is withdrawing its draft guidance on dermatopharmacokinetics based on input from the public, agency advisory committees, FDA announces in May 17 Federal Register. Comments raised "substantial doubt" regarding the adequacy of DPK to assess bioequivalence of topical dermatological drugs because such products address a variety of diseases on different parts of the skin, not just stratum corneum, FDA explains. Reproducibility of the method between labs also was questioned. Agency plans to "explore the development of new methods and improvements in current methods" for documenting bioequivalence of topical dermatologicals...
You may also be interested in...
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.
Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug; FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.
FerGene bladder cancer therapy achieved a complete response in more than half of patients in its pivotal trial. The joint venture now looks to commercialization and potential expansion of indications.